ITCI Aug 2022 40.000 call
| Previous Close | 17.60 |
| Open | N/A |
| Bid | 11.60 |
| Ask | 13.10 |
| Strike | 40.00 |
| Expire Date | 2022-08-19 |
| Day's Range | 17.60 - 17.60 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
- Motley Fool
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia. In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.
- Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
- Motley Fool
Why Intra-Cellular Therapies Trounced the S&P 500 Today
For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December. Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit.
